<DOC>
	<DOCNO>NCT00978393</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate effect liraglutide gastric emptying , energy expenditure appetite , evaluate liraglutide pharmacokinetics non-diabetic obese volunteer . The trial design two-period , six-sequenced , crossover trial trial participant enter two treatment period wash-out period 6-8 week .</brief_summary>
	<brief_title>A Trial Assess Effect Liraglutide Gastric Emptying Healthy Obese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body Mass Index ( BMI ) 30.040.0 kg/m2 Stable body weight ( 5 kg body weight change past 3 month ) Fasting plasma glucose 7.0 mmol/L Presence history cancer clinically significant cardiac , metabolic , renal , gastrointestinal , hepatic , endocrine , dermatological , haematological , psychiatric disease disorder , consider Investigator influence result trial History chronic pancreatitis idiopathic acute pancreatitis Current history treatment medication may cause significant weight gain , within 12 month prior screen Use weight lower pharmacotherapy within last 3 month prior trial start Previous schedule ( trial period ) surgical treatment obesity Diagnosed type 1 type 2 diabetes Smoking habitually judge Investigator Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method sterile postmenopausal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>